TREVENTIS research will make a meaningful difference in the lives of patients with Alzheimer’s disease (AD) by discovering and developing novel drugs that may halt the progression of AD, stabilize and potentially improve the patient’s cognition. Our proprietary discovery platform allows for rapid identification of promising new chemical entities as potential therapeutics in both AD and other protein misfolding disorders such as Parkinson’s and Huntington’s disease.
Contact Information
TREVENTIS Corporation
1411 Oxford St
Halifax, NS
B3H 3Z1
- 902.431.4902 – Phone
- 902.431.4741 – Fax
- Chris Barden mreed@treventis.com
Return to Members Directory
